- A meta-analysis examining the effectiveness of a new surgical procedure finds that studies published in high-impact journals show larger effect sizes than studies published in specialty journals, despite similar methodological quality. This pattern most likely suggests:
Answer: Publication bias favoring dramatic results in high-impact venues
When you encounter questions about patterns in research findings across different publication venues, think about the various biases that can affect what gets published and where.
The scenario describes studies of similar methodological quality showing different effect sizes based solely on journal prestige. This pattern strongly indicates publication bias - the tendency for journals, especially high-impact ones, to preferentially publish studies with dramatic, statistically significant, or novel results. High-impact journals often seek studies that will generate citations and attention, creating pressure to publish research with larger effect sizes even when methodology is comparable across venues.
Option A is incorrect because superior peer review would actually lead to more consistent, not inflated, effect sizes across studies of similar quality. Better peer review typically reduces bias rather than creating systematic differences in reported effects.
Option B assumes surgical technique varies by submission venue, but there's no logical reason why researchers using better techniques would systematically choose high-impact journals over specialty journals, especially since specialty journals often have more relevant expert reviewers.
Option D suggests statistical analysis quality differs by journal type, but the question states methodological quality is similar across venues. More rigorous statistics would likely reduce effect sizes by controlling for confounding variables, not inflate them.
Study tip: When you see systematic differences in research outcomes that correlate with publication prestige rather than study quality, always consider publication bias first. This is a common issue in meta-analyses and evidence-based medicine questions.
- An investigator studying cancer treatment effectiveness has received speaking honoraria from five different pharmaceutical companies over the past three years. When submitting a manuscript about cancer therapy, the investigator lists only the two companies whose drugs were mentioned in the current study. This disclosure approach is:
Answer: Inadequate because all pharmaceutical relationships could influence cancer research
When evaluating conflicts of interest in biomedical research, you need to understand that disclosure requirements are deliberately broad because potential influences can be subtle and far-reaching. The key principle is that any financial relationship that could reasonably be perceived as creating bias should be disclosed, regardless of whether it directly relates to the specific study.
Option B is correct because all pharmaceutical relationships could potentially influence how an investigator approaches, designs, or interprets cancer research. Even if the investigator received speaking fees from companies whose drugs aren't mentioned in the current study, those relationships could still create unconscious biases about treatment approaches, competitor products, or research priorities. The "appearance of impropriety" standard requires disclosure of all relevant relationships within a specified timeframe (typically 3-5 years).
Option A incorrectly assumes that only direct relationships matter, missing the broader principle that any pharmaceutical relationship could influence cancer research perspectives. Option C underestimates the significance of speaking honoraria—these payments can create meaningful financial relationships and loyalty to specific companies. Option D misunderstands disclosure requirements entirely; speaking fees, consulting arrangements, and research funding all require disclosure, not just research funding.
Study tip: Remember that conflict of interest disclosure follows the "when in doubt, disclose it" principle. On biostatistics exams, questions about research ethics typically test whether you understand that disclosure requirements are intentionally comprehensive to maintain public trust in research, even if some relationships seem tangentially related.
- A systematic review finds that 15 published studies show positive effects of a new therapy, while 3 show no effect. However, a search of trial registries reveals 8 additional completed but unpublished studies. If these unpublished studies were more likely to have negative results, what bias does this scenario best illustrate?
Answer: Publication bias creating an incomplete evidence base for review
When you encounter questions about biases in systematic reviews or meta-analyses, focus on distinguishing between biases that occur within individual studies versus those that affect which studies make it into the review itself.
This scenario describes publication bias, where studies with positive or statistically significant results are more likely to be published than those with negative or null findings. The key evidence here is that 8 completed studies remain unpublished and are suspected to have negative results. This creates a skewed evidence base where the systematic review only captures the "successful" studies, making the therapy appear more effective than it actually is.
Option A is incorrect because selection bias refers to how participants are chosen within individual studies, not which studies get published. The bias here isn't about who was enrolled in the trials, but about which completed trials became available for review.
Option B addresses information bias, which involves measurement errors or misclassification within studies. The problem isn't that outcomes were measured poorly—it's that entire studies with certain types of results are missing from the published literature.
Option D describes reporting bias, where researchers selectively report only favorable outcomes from within their studies while omitting negative findings from the same study. Here, the issue is that entire studies are missing, not selective reporting within published studies.
Remember this pattern: when you see "unpublished studies" or "studies sitting in file drawers" combined with suspicion that these missing studies have different results than published ones, think publication bias immediately.
- A pharmaceutical company funds a clinical trial of their new cholesterol medication. The study protocol requires reporting all adverse events, but the company's internal emails reveal they discussed ways to minimize reporting of mild gastrointestinal side effects in the final publication. Which type of bias is most directly illustrated by this scenario?
Answer: Reporting bias due to selective presentation of outcomes
When you encounter questions about bias in clinical research, focus on identifying what specific aspect of the study design or conduct is being compromised. This scenario illustrates a clear case of selective information presentation after data collection is complete.
The company's internal discussions about minimizing the reporting of mild gastrointestinal side effects represents reporting bias (answer B). This occurs when researchers selectively present, emphasize, or suppress certain findings in their publications. Even though the study protocol required reporting all adverse events, the company planned to downplay specific negative outcomes in their final publication. This creates a distorted picture of the medication's true safety profile for readers and future prescribers.
Let's examine why the other options don't fit: Answer A (selection bias) involves problems with how participants are chosen for the study, not how results are reported afterward. Answer C (recall bias) refers to participants' inability to accurately remember past events or exposures, which isn't relevant since this involves the company's reporting decisions, not participant memory. Answer D (observer bias) occurs when researchers' expectations influence how they measure or assess outcomes during the study, but here the bias happens at the publication stage, not during data collection.
Study tip: Remember that reporting bias occurs after data collection and involves selective presentation of results. Look for keywords like "discussed ways to minimize," "chose not to publish," or "emphasized positive findings" to identify this type of bias on exam questions.
- A pharmaceutical company sponsors a clinical trial but contractually requires that all publications must be approved by the company before submission. The investigators agree to this arrangement. This contract provision most directly threatens:
Answer: The independence of scientific reporting and interpretation
When you encounter questions about research ethics and contractual arrangements in clinical trials, focus on how external pressures might compromise the scientific process. The key issue here is identifying which aspect of research integrity is most directly at risk.
The requirement for company approval before publication creates a fundamental conflict between scientific objectivity and commercial interests. This arrangement directly threatens the independence of scientific reporting and interpretation (C) because it gives the sponsor veto power over how results are presented, analyzed, and discussed. Researchers might feel pressured to downplay negative findings, emphasize positive results, or modify their interpretation to align with the company's commercial interests. This compromises the core principle that scientific conclusions should be based solely on data and evidence, not influenced by financial stakeholders.
Option A is incorrect because the statistical analysis methods themselves aren't necessarily compromised—the study can still use appropriate statistical techniques. The threat is to how those results are reported, not how they're calculated. Option B misses the mark because the reliability of outcome measurements isn't affected by publication approval requirements—the data collection process remains intact. Option D is wrong because sample size calculations are typically determined during study design, well before any publication approval issues arise.
Remember that research ethics questions often test your ability to distinguish between threats to data integrity (how studies are conducted) versus threats to scientific integrity (how results are reported and interpreted). Publication control arrangements always raise red flags about scientific independence, even when the underlying research methodology remains sound.
- Assuming both studies were methodologically sound, what factor most likely explains the discrepant findings between these two research groups?
Answer: Group B's commercial funding likely influenced outcome selection, measurement, or analysis decisions
Given the commercial interest in positive results, Group B's funding source most likely influenced subtle decisions about outcome selection, measurement timing, subgroup analyses, or statistical approaches (C). While larger sample size (A) could contribute, a 20% increase typically wouldn't shift results from p=0.24 to p=0.04. Government funding doesn't inherently create conservative bias (B), and random variation (D) is less likely to explain such systematic differences between funding sources.
- Given that both groups of studies met quality standards, what is the most likely explanation for the systematic difference in reported effect sizes?
Answer: Subtle biases in study design, conduct, or analysis influenced industry-funded studies toward more favorable results
When you encounter questions about systematic differences in research outcomes based on funding source, you're dealing with research bias and conflict of interest issues—key concepts in evidence-based medicine and meta-analysis interpretation.
The striking difference in effect sizes (0.8 vs 0.3) between industry-funded and independently-funded studies, despite both meeting quality criteria, points to subtle but systematic bias. Answer A correctly identifies that industry funding can introduce unconscious biases throughout the research process—from how endpoints are defined and measured, to which analyses are emphasized in reporting, to decisions about study duration or population selection. These biases can occur even in methodologically sound studies and are well-documented in medical literature.
Answer B is incorrect because independent funders don't typically impose more stringent statistical requirements—if anything, they often have fewer restrictions on analysis approaches. Answer C misses the mark because larger sample sizes would increase precision (narrower confidence intervals), not necessarily inflate effect sizes. The confidence intervals shown don't suggest the industry studies had dramatically larger samples. Answer D assumes manufacturer studies used different populations, but this would typically be noted as a limitation in study selection criteria rather than appearing as a systematic pattern across multiple studies meeting the same inclusion standards.
Study tip: When reviewing systematic reviews or meta-analyses, always examine funding sources and look for patterns in results based on who sponsored the research. This type of funding bias is a classic exam topic because it's so prevalent in real-world evidence evaluation.
- A university researcher collaborates with a biotechnology company on a joint research project. The company provides funding and laboratory facilities, while the university provides scientific expertise. When publishing results, what disclosure approach best addresses potential conflicts?
Answer: Disclose the collaboration, funding, and any individual financial relationships
When evaluating research conflicts of interest, transparency is the cornerstone of ethical scientific practice. Academic-industry collaborations create complex relationship webs that can influence research design, data interpretation, and publication decisions, even when researchers maintain the highest integrity.
The correct approach requires comprehensive disclosure of all relevant relationships. Option C correctly captures this principle by requiring disclosure of the collaboration itself, the funding arrangements, and any individual financial relationships between researchers and the company. This complete transparency allows readers, reviewers, and the scientific community to evaluate potential biases and interpret results appropriately.
Option A fails because limiting disclosure to direct financial support ignores other influential factors like facility access, equipment provision, or future collaboration prospects that could unconsciously shape research decisions. Option B represents a dangerous misconception—legitimacy doesn't eliminate conflict of interest. Even ethically sound collaborations create potential conflicts that must be disclosed. Option D is particularly problematic because it suggests selective disclosure based on results, which undermines scientific integrity. Conflicts exist regardless of whether findings favor the sponsor, and determining what "favors" a company can be subjective and complex.
Remember this key principle for biostatistics ethics questions: when in doubt, err on the side of over-disclosure rather than under-disclosure. The goal isn't to avoid all industry collaborations—they're often valuable—but to maintain transparency so the scientific community can properly evaluate the research within its full context.
- A meta-analysis of antidepressant effectiveness shows strong positive results. However, the authors only included published studies and excluded unpublished trials with negative results that were registered in clinical trial databases. This limitation most directly represents:
Answer: Publication bias affecting the overall evidence base being analyzed
When you encounter questions about systematic reviews and meta-analyses, focus on identifying different types of bias that can affect the validity of the pooled evidence. The key distinction is whether the bias occurs within individual studies or in how studies are selected for inclusion.
This scenario describes a classic case of publication bias. The meta-analysis authors systematically excluded unpublished negative trials that were registered in databases, meaning they only analyzed studies that made it to publication. This creates a skewed evidence base because negative results are less likely to be published, leading to an overly optimistic pooled effect estimate. Publication bias affects which studies enter the literature and become available for systematic review.
Option A is incorrect because reporting bias occurs within individual studies when authors selectively report favorable outcomes while suppressing unfavorable ones. Here, the bias isn't happening within each included study, but rather in which studies get included.
Option B misses the mark because selection bias in patient populations would involve choosing non-representative study participants. The issue here isn't about who was studied, but about which completed studies were analyzed.
Option D is wrong because observer bias involves systematic errors in how outcomes are measured or assessed. The measurement methods aren't the problem—the problem is the systematic exclusion of negative studies from the analysis.
Remember: Publication bias is a major threat to meta-analyses. Always check whether authors searched for unpublished studies, conference abstracts, and trial registries. The phrase "file drawer problem" refers to this same concept.
- A researcher analyzing clinical trial data discovers that including all randomized patients shows no significant treatment benefit, but excluding patients who discontinued treatment early shows significant benefit. The published paper presents only the analysis excluding early discontinuations. This approach most directly represents:
Answer: Selective analysis reporting based on statistical significance
When you encounter questions about research reporting practices, focus on the ethical principles of transparency and avoiding bias in how results are presented.
This scenario describes a classic case of selective reporting based on statistical significance. The researcher conducted two analyses: an intention-to-treat (ITT) analysis including all randomized patients (showing no benefit) and a per-protocol analysis excluding early discontinuations (showing benefit). Publishing only the favorable result while omitting the unfavorable one constitutes selective reporting, which can mislead readers about the true treatment effect.
Choice C correctly identifies this as selective analysis reporting based on statistical significance. The researcher cherry-picked results that supported their hypothesis while suppressing contradictory findings.
Choice A is incorrect because while per-protocol analyses can be appropriate for regulatory submissions, they should be presented alongside ITT analyses, not as replacements. Presenting only favorable results isn't appropriate regardless of the submission type.
Choice B is wrong because standard practice requires reporting both ITT and per-protocol analyses when both are conducted. Transparency demands showing all planned analyses, especially when results differ substantially.
Choice D mischaracterizes the situation as a necessary adjustment. While excluding non-adherent participants can provide valuable insights, doing so selectively based on whether results reach significance represents bias, not scientific necessity.
Remember this key principle: legitimate research requires transparent reporting of all conducted analyses, especially when results conflict. Watch for scenarios where researchers present only favorable findings while hiding unfavorable ones—this always signals selective reporting bias.
- A clinical trial protocol specifies five primary endpoints, but the published paper emphasizes only the two endpoints that showed statistically significant results, while briefly mentioning the three non-significant endpoints in a table. This practice primarily represents:
Answer: Selective reporting bias that misrepresents the study's overall results
When you encounter questions about research reporting practices, focus on the fundamental principle that scientific integrity requires transparent presentation of all pre-specified outcomes, regardless of their statistical significance.
This scenario describes selective reporting bias (also called outcome reporting bias), where researchers emphasize favorable results while downplaying unfavorable ones. The protocol specified five primary endpoints — these are the main outcomes the study was designed and powered to detect. By highlighting only the two significant results while burying the three non-significant ones in a table, the authors misrepresent their study's overall findings and violate scientific reporting standards.
Option A is incorrect because clinically meaningful findings should include both positive and negative results — knowing what doesn't work is often as valuable as knowing what does. Option C mischaracterizes this as standard practice, when in fact it represents poor scientific conduct that journals and regulatory agencies actively discourage. Option D incorrectly suggests space constraints justify selective emphasis of pre-specified primary endpoints; primary outcomes should receive equal prominence regardless of their significance.
This selective presentation can mislead readers about treatment effectiveness and contribute to publication bias in systematic reviews and meta-analyses. The appropriate approach would be to present all five primary endpoints with equal emphasis, discussing the clinical implications of both significant and non-significant findings.
Study tip: Remember that pre-specified primary endpoints must be reported transparently regardless of significance. When you see questions about emphasizing only positive results while downplaying negative ones, think "selective reporting bias."
- Which aspect of this funding agreement poses the greatest threat to research integrity and unbiased reporting?
Answer: The termination clause based on research direction alignment with company objectives
The termination clause tied to 'mutually agreed objectives' (D) poses the greatest threat because it allows the sponsor to end funding if research doesn't align with their interests, creating powerful incentive to bias research direction and results. While manuscript review rights (B) are concerning, the termination threat is more coercive. Large funding amounts (A) alone don't create bias, and reasonable patent delays (C) are often acceptable if time-limited and disclosed.
- A systematic review of vaccine safety includes 20 published studies showing vaccines are safe, but excludes 5 unpublished studies with similar methodology that found no safety concerns. The review authors excluded the unpublished studies because they "lack peer review." This decision most likely introduces:
Answer: Publication bias by preferring published over unpublished work
When evaluating systematic reviews and meta-analyses, you need to recognize different types of bias that can compromise the validity of findings. This question tests your ability to distinguish between various forms of bias based on how studies are selected and included.
The scenario describes authors excluding unpublished studies solely because they "lack peer review," despite having similar methodology and findings. This represents publication bias – the systematic tendency to preferentially include published studies over unpublished ones. Publication bias occurs when study selection is based on publication status rather than methodological quality, potentially skewing results since published studies may differ systematically from unpublished ones.
Let's examine why the other options don't fit: Option A (Selection bias) is too broad and doesn't capture the specific mechanism at work. While technically a form of selection bias, the more precise term for bias based on publication status is publication bias. Option B (Information bias) refers to systematic errors in data collection or measurement within studies, not in study selection for a review. Option D (Reporting bias) occurs within individual studies when authors selectively report certain outcomes or analyses, not when review authors exclude entire studies based on publication status.
Study tip: Remember that publication bias specifically refers to the preferential inclusion of published over unpublished work in systematic reviews. When you see questions about excluding studies based on publication status rather than methodological quality, publication bias should be your first consideration. This is a critical concept in evidence-based medicine and meta-analysis.
- An epidemiologist receives a research grant from an environmental advocacy organization to study air pollution health effects. The organization's mission is to demonstrate environmental health harms. When reporting this funding source, what additional step would best address potential conflicts of interest?
Answer: Acknowledge the funder's advocacy mission and describe steps taken to ensure objectivity
When you encounter questions about conflicts of interest in research, focus on the principle of transparency with mitigation rather than avoidance at all costs. Research funding often comes from organizations with specific interests, and the goal is to maintain scientific integrity while acknowledging potential biases.
The best approach is to acknowledge the funder's advocacy mission and describe steps taken to ensure objectivity (B). This demonstrates transparency by fully disclosing not just who provided funding, but their potential motivations. More importantly, it shows that the researcher has actively considered how bias might influence the study and has implemented safeguards like independent data analysis, peer review, or predetermined protocols to maintain objectivity.
Option A (returning the funding) is unnecessarily extreme and would severely limit research funding sources, as many organizations have some advocacy component. Option C (disclosing only the amount) fails to provide readers with crucial information about potential bias sources - the funder's mission is often more relevant than the dollar amount. Option D (delaying publication) is impractical since truly "neutral" funding sources are rare, and this would unnecessarily delay important research from reaching the public.
The key principle here is that conflicts of interest aren't automatically disqualifying - they need to be managed and disclosed transparently. Readers can then evaluate the research with full knowledge of potential biases.
Study tip: Remember that in biostatistics and research ethics, transparency plus mitigation typically beats avoidance. Look for answers that acknowledge potential problems while describing concrete steps to address them.
- A pharmaceutical company conducts a clinical trial and registers the primary endpoint as 'cardiovascular mortality at 12 months.' The published results report the primary endpoint as 'composite cardiovascular events at 6 months,' showing statistically significant results (p=0.02). The originally registered endpoint showed no significant difference (p=0.18). How should this discrepancy be interpreted?
Answer: The modification demonstrates selective outcome reporting bias, likely to achieve statistical significance and favorable results
Changing from the registered primary endpoint (mortality at 12 months) to a different endpoint (composite events at 6 months) that happens to show significant results while the original endpoint was negative represents classic selective outcome reporting bias (B). This practice inflates the likelihood of finding significant results. Protocol optimization (A) would involve pre-specified interim analysis rules, broader endpoints aren't necessarily more relevant (C), and regulatory evolution doesn't justify post-hoc endpoint changes (D).
- Which aspect of this study represents the most significant threat to the validity of the reported findings due to conflicts of interest?
Answer: The company's medical affairs team participated in designing the study methodology and analysis approach
The most significant threat is the sponsor's direct involvement in study design and statistical analysis plan (C), as this creates the highest risk for bias in how outcomes are measured and analyzed. While investigator payments (B) and complete industry funding (A) are concerning conflicts, they don't directly compromise scientific methodology. A borderline p-value (D) suggests potential selective reporting but isn't itself a conflict of interest.
- An investigator studying dietary supplements has received consulting fees from three different supplement manufacturers over the past two years. When submitting a manuscript about supplement safety, which disclosure approach best addresses potential conflicts of interest?
Answer: Disclose all financial relationships with supplement companies regardless of study focus
When you encounter questions about conflicts of interest in research, think about the fundamental principle: transparency protects scientific integrity and public trust. The goal isn't just to avoid actual bias, but to allow readers to identify any potential sources of bias.
The correct approach is to disclose all financial relationships with supplement companies regardless of study focus (C). This comprehensive disclosure standard exists because conflicts of interest can be subtle and far-reaching. Even if a researcher studied Company A's products but received consulting fees from Companies B and C, those relationships could still influence how they frame questions, interpret data, or draw conclusions about the supplement industry broadly. Readers deserve to know about all potential conflicts so they can evaluate the research appropriately.
Option A is wrong because funding source isn't the only relevant financial relationship—consulting fees, speaking honoraria, and other payments can all create conflicts. Option B fails because limiting disclosure to only the specific products studied ignores how industry relationships can create broader biases toward favorable interpretations of supplement research generally. Option D incorrectly suggests that disclosure depends on whether conflicts actually influenced conclusions, but researchers often can't objectively assess their own bias, and the appearance of conflict matters as much as actual influence.
Study tip: Remember that conflict of interest disclosure follows a "when in doubt, disclose" principle. On biostatistics exams, questions about research ethics typically favor the most transparent, comprehensive approach to maintaining scientific integrity.
- A clinical trial protocol lists "cardiovascular events" as the primary endpoint, but the published paper focuses on "cardiovascular mortality" (a subset of the original endpoint) because the broader endpoint was not statistically significant. The mortality endpoint was significant. This change represents:
Answer: Selective outcome reporting that changes pre-specified endpoints
When you encounter questions about changes between trial protocols and published results, you're being tested on research integrity and selective outcome reporting - a critical issue in evidence-based medicine.
This scenario describes a classic case of selective outcome reporting bias. The researchers pre-specified "cardiovascular events" as their primary endpoint in the protocol, but when this broader measure didn't reach statistical significance, they shifted focus to the narrower "cardiovascular mortality" subset that did show significance. This practice undermines the validity of statistical inference because it increases the chance of finding spurious significant results through multiple testing.
Option C correctly identifies this as selective outcome reporting that changes pre-specified endpoints. The key red flag here is that the change was driven by statistical results rather than scientific rationale.
Option A is wrong because appropriate endpoint refinement should be based on clinical considerations established before seeing results, not statistical outcomes. Option B incorrectly suggests this is standard practice - while focusing on meaningful outcomes is important, changing endpoints post-hoc based on significance is considered poor methodology. Option D is incorrect because the scenario provides no evidence of "unexpected event patterns" - the change appears motivated solely by achieving statistical significance.
Remember this pattern: When protocols and publications differ regarding endpoints, especially when changes favor significant results, suspect selective reporting bias. This is a major threat to research validity that regulatory agencies and journals actively combat through trial registration requirements.
- A researcher's spouse owns stock in a medical device company. The researcher is conducting a study comparing surgical outcomes using different types of medical devices, including devices made by the spouse's company. What is the most appropriate action regarding this potential conflict?
Answer: Disclose the spouse's financial interest when publishing results
Biostatistics research operates under strict ethical guidelines for managing conflicts of interest, particularly financial relationships that could bias study design, analysis, or interpretation. When you encounter questions about research ethics, focus on transparency and disclosure rather than elimination of all potential conflicts.
The most appropriate action is disclosure of the spouse's financial interest when publishing results (C). Research integrity doesn't require researchers to be completely free of all potential conflicts—this would be nearly impossible in practice. Instead, the scientific community relies on transparent reporting so readers can evaluate potential bias themselves. Professional journals and institutions have established disclosure requirements specifically for this purpose. By openly reporting the spouse's stock ownership, the researcher maintains scientific integrity while allowing peers to assess the research with full knowledge of potential influences.
Option A is incorrect because spousal financial interests are considered conflicts of interest even when the researcher doesn't directly own the stock—family financial benefits can still create unconscious bias. Option B goes too far by excluding relevant data from analysis, which could actually compromise the study's scientific validity and completeness. Option D represents an attempt to hide the conflict rather than address it transparently, and timing the transfer around publication suggests awareness that the conflict exists but willingness to conceal it.
Remember that in biostatistics ethics questions, disclosure and transparency are almost always preferred over elimination or concealment of conflicts. The goal is informed evaluation by the scientific community, not perfect isolation from all potential influences.
- A meta-analysis of 15 studies on a controversial medical intervention shows strong evidence of publication bias, with a funnel plot demonstrating significant asymmetry and Egger's test yielding p=0.008. The authors identify that 12 of the 15 included studies were industry-funded. What is the most appropriate interpretation of these findings?
Answer: The combination of publication bias and predominant industry funding suggests systematic overestimation of treatment benefits
The combination of significant publication bias (evidenced by funnel plot asymmetry and Egger's test) with predominantly industry-funded studies strongly suggests systematic overestimation of benefits (C). This doesn't completely invalidate results (A) but indicates bias beyond just methodological validity (B). Industry funding can bias publication regardless of result direction (D), as sponsors may suppress unfavorable findings through various mechanisms.
